• Nachrichtendetail
• 

13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS

	Name	WKN	Börse	Kurs	Datum/Zeit	Diff.	Diff. %	Geld	Brief	Erster	Schluss
	SANOFI SA INHABER EO 2	920657	Frankfurt	90,210	27.06.24 08:08:34	-0,670	-0,74%	90,230	90,350	90,210	90,880
	REGENERON PHARMAC.DL-,001	881535	Frankfurt	993,000	27.06.24 08:12:54	-13,500	-1,34%	992,400	1.004,000	993,000	1.006,500